Raymond James & Associates Pro Qr Therapeutics N.V. Transaction History

Raymond James & Associates

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 25, 2023	SELL	$1.62 - $2.32 $3,240 - $4,640	-2,000 Reduced 8.87%	20,550 $33,000
Q1 2023 Apr 14, 2023	BUY	$1.99 - $3.66 $1,990 - $3,660	1,000 Added 4.64%	22,550 $48,000
Q4 2022 Feb 08, 2023	SELL	$0.8 - $3.7 $23,688 - $109,560	-29,611 Reduced 57.88%	21,550 $79,000
Q3 2022 Oct 25, 2022	BUY	$0.74 - $0.89 $37,859 - $45,533	51,161 New	51,161 $38,000
Q2 2021 Aug 11, 2021	SELL	$5.75 - $7.59 $230,000 - $303,600	-40,000 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$4.14 - $9.22 $165,600 - $368,800	40,000 New	40,000 $264,000

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $191M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.